Please login to the form below
Combination treatment
This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.
BMS eyes approval for second Opdivo combo in kidney cancer
However, it has been facing competition from Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (ipilimumab) after the combination treatment won US Food and Drug ... combination treatment.
Latest news
-
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19
The combination treatment hit the primary study endpoint of a reduction in recovery time. ... The combination treatment also met the secondary endpoint of comparing patient outcomes at day 15, using an ordinal eight-point scale ranging from fully
-
Janssen scores another expansion for new Darzalex combination in the US
The FDA has approved the expanded use of Darzalex (daratumumab) and dexamethasone in both once- and twice-weekly dosing regimens in combination with Kyprolis (carfilzomib), for the treatment of patients with ... It also has an approval for another
-
NICE recommends Roche’s Polivy for B-cell lymphoma
According to NICE, around 4, 800 people in England have DLBCL, with around 530 of those eligible for the new Polivy (polatuzumab vedotin) combination treatment. ... NICE said that the cost-effectiveness of the Polivy combination treatment was ‘very
-
BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme
As well as testing the drug as a mono therapy, Dragonfly is also studying DF6002 in combination with PD-1 inhibiting treatment, such as BMS’ Opdivo (nivolumab). ... Dragonfly also signed a deal with Celgene, now owned by BMS, in 2017 and 2018 for a
-
AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
The median OS for patients receiving the Venclyxto combination treatment was 14.7 months versus 9.6 months in the placebo arm, with the treatment also reducing the risk of death ... The safety profile of the treatment was found to be generally consistent
More from news
Approximately 0 fully matching, plus 273 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
-
Deal Watch April 2016
Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
-
Pharma deals in April 2015
No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. . ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
-
Pharma deals during July 2014
Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business
-
Interview: AstraZeneca's Susan Galbraith
And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Oncosec
body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
-
Marketing strategy in complex environments
The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Gilead agrees $21bn buyout of Immunomedics
- New medical communications agency BOLDSCIENCE launches
- Moderna inks R&D agreements with Vertex and Chiesi
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- FDA approves Roche’s Actemra COVID-19 trial
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
Creative Medical Research
Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
